| Year |
Citation |
Score |
| 2013 |
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J. Putting the Alzheimer's cognitive test to the test II: Rasch Measurement Theory. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: S10-20. PMID 23253779 DOI: 10.1016/J.Jalz.2012.08.006 |
0.331 |
|
| 2013 |
Hobart J, Cano S, Posner H, Selnes O, Stern Y, Thomas R, Zajicek J. Putting the Alzheimer's cognitive test to the test I: traditional psychometric methods. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 9: S4-9. PMID 23253777 DOI: 10.1016/J.Jalz.2012.08.005 |
0.329 |
|
| 2011 |
Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 76: 1389-94. PMID 21502597 DOI: 10.1212/Wnl.0B013E318216Eb7B |
0.356 |
|
| 2010 |
Quinn JF, Thomas R, Raman R, Yurko-Mauro K, Bailey-Hall E, Nelson E, Shaw L, Aisen P. Cerebrospinal fluid biomarker outcomes in a trial of docosahexaenoic acid (DHA) for Alzheimer's disease Alzheimers & Dementia. 6. DOI: 10.1016/J.Jalz.2010.05.1002 |
0.307 |
|
| 2008 |
Quinn JF, Raman R, Thomas R, Ernstrom K, Yurko-Mauro K, Nelson E, Aisen PS. P4-343: Omega 3 fatty acids and Alzheimer's disease: Trial design and baseline study population characteristics in a clinical trial of docosahexanoic acid for Alzheimer's disease Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2413 |
0.336 |
|
| 2008 |
Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, Hung D. P4-337: Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study Alzheimers & Dementia. 4. DOI: 10.1016/J.Jalz.2008.05.2407 |
0.33 |
|
| 2007 |
May S, Gilman S, Sowell BB, Thomas RG, Stern MB, Colcher A, Tanner CM, Huang N, Novak P, Reich SG, Jankovic J, Ondo WG, Low PA, Sandroni P, Lipp A, et al. Potential outcome measures and trial design issues for multiple system atrophy. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 2371-7. PMID 17914727 DOI: 10.1002/Mds.21734 |
0.303 |
|
| 2005 |
Tariot PN, Raman R, Jakimovich L, Schneider L, Porsteinsson A, Thomas R, Mintzer J, Brenner R, Schafer K, Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: A randomized, controlled trial American Journal of Geriatric Psychiatry. 13: 942-949. PMID 16286437 DOI: 10.1097/00019442-200511000-00004 |
0.361 |
|
| 2005 |
Galasko D, Schmitt F, Thomas R, Jin S, Bennett D. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychological Society : Jins. 11: 446-53. PMID 16209425 DOI: 10.1017/S1355617705050502 |
0.339 |
|
| 2005 |
Peskind ER, Tsuang DW, Bonner LT, Pascualy M, Riekse RG, Snowden MB, Thomas R, Raskind MA. Propranolol for disruptive behaviors in nursing home residents with probable or possible Alzheimer disease: A placebo-controlled study Alzheimer Disease and Associated Disorders. 19: 23-28. PMID 15764868 DOI: 10.1097/01.Wad.0000155067.16313.5E |
0.301 |
|
| 2004 |
Tariot PN, Thal L, Jakimovich L, Thomas R, Raman R. P1-322 A multicenter, randomized, double-blind, placebo-controlled trial of valproate for agitation associated with dementia Neurobiology of Aging. 25. DOI: 10.1016/S0197-4580(04)80635-3 |
0.315 |
|
| 2003 |
Grundman M, Capparelli E, Kim HT, Morris JC, Farlow M, Rubin EH, Heidebrink J, Hake A, Ho G, Schultz AN, Schafer K, Houston W, Thomas R, Thal LJ. A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sciences. 73: 539-53. PMID 12770610 DOI: 10.1016/S0024-3205(03)00320-5 |
0.318 |
|
| 2000 |
Mulnard RA, Cotman CW, Kawas C, Dyck CHv, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Gamst A, Grundman M, Thomas R. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease: A Randomized Controlled Trial Obstetrical & Gynecological Survey. 439-440. DOI: 10.1097/00006254-200007000-00021 |
0.321 |
|
| 1999 |
Sabbagh MN, Corey-Bloom J, Tiraboschi P, Thomas R, Masliah E, Thal LJ. Neurochemical markers do not correlate with cognitive decline in the Lewy body variant of Alzheimer disease. Archives of Neurology. 56: 1458-61. PMID 10593300 DOI: 10.1001/Archneur.56.12.1458 |
0.301 |
|
| 1997 |
Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S. An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease Alzheimer Disease & Associated Disorders. 11: 33-39. DOI: 10.1097/00002093-199700112-00005 |
0.363 |
|
| 1996 |
Sano M, Ernesto C, Klauber MR, Schafer K, Woodbury P, Thomas R, Grundman M, Growdon J, Thal LJ. Rationale and design of a multicenter study of selegiline and alpha-tocopherol in the treatment of Alzheimer disease using novel clinical outcomes. Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders. 10: 132-40. PMID 8876776 DOI: 10.1097/00002093-199601030-00004 |
0.37 |
|
| Show low-probability matches. |